(Q35640461)

English

Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C

scientific article published on January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C (English)

1 reference

Europe PubMed Central

9 August 2017

toll-like receptor

0 references

decision making

1 reference

based on heuristic

inferred from title

author name string

Hannah M Jones

1

1 reference

Europe PubMed Central

9 August 2017

Phylinda L S Chan

2

1 reference

Europe PubMed Central

9 August 2017

Piet H van der Graaf

3

1 reference

Europe PubMed Central

9 August 2017

Robert Webster

4

1 reference

Europe PubMed Central

9 August 2017

language of work or name

0 references

publication date

1 January 2012

1 reference

Europe PubMed Central

9 August 2017

British Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

9 August 2017

73

1 reference

Europe PubMed Central

9 August 2017

1

1 reference

Europe PubMed Central

9 August 2017

77-92

1 reference

Europe PubMed Central

9 August 2017

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Toll-like receptors and adaptor molecules in liver disease: update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Investigating Toll-Like Receptor Agonists for Potential To Treat Hepatitis C Virus Infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Global challenges in liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Immune response modifiers--mode of action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Innate immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Effects of alpha-interferon on theophylline pharmacokinetics and metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Clinical Pharmacokinetics of Interferons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Decrease in the activity of the drug-metabolizing enzymes of rat liver following the administration of tilorone hydrochloride

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

27 July 2018

Interferons alpha and beta as immune regulators--a new look

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04047.X

21 January 2018

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04047.X

21 January 2018

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04047.X

21 January 2018

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04047.X

21 January 2018

The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04047.X

21 January 2018

Effect of interferon treatment on serum 2',5'-oligoadenylate synthetase levels in hepatitis C-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04047.X

21 January 2018

Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04047.X

21 January 2018

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04047.X

21 January 2018

Side effects of therapy of hepatitis C and their management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

25 September 2018

Cutting Edge: Overlapping Functions of TLR7 and TLR9 for Innate Defense against a Herpesvirus Infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04047.X

21 January 2018

Cutting edge: Overlapping functions of TLR7 and TLR9 for innate defense against a herpesvirus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3248258

7 December 2018

Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/21689140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum interferon level and (2'-5')oligoadenylate synthetase activity in lymphocytes during clinical interferon application

1 reference

https://pubmed.ncbi.nlm.nih.gov/21689140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2125.2011.04047.X

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35640461&oldid=1524568993"